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mellonella model of multidrug-resistant
Pseudomonas aeruginosa infection
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Abstract
Background: This study aimed to evaluate the efficacy of combinations of steroidal alkaloids and conessine from the
Thai medicinal plant Holarrhena antidysenterica with antibiotics against Pseudomonas aeruginosa strains possessing
different efflux-pump-mediated multidrug-resistant (MDR) phenotypes in a Galleria mellonella infection model.
Methods: P. aeruginosa strains with defined mutations that result in the overexpression of the MexAB-OprM, MexCD-OprJ
and MexEF-OprN efflux pumps, and a strain with all three of these pumps deleted, were used. In vitro, the effect of
combinations of steroidal alkaloids and conessine with antibiotics was compared with antibiotic treatment alone via MIC
determination and time-kill assays. Efficacy of combinations of the steroidal alkaloids and conessine with levofloxacin were
compared with monotherapies against infections in G. mellonella larvae by measuring larval mortality and bacterial burden.
Results: Combination therapies of conessine or steroidal alkaloids with levofloxacin enhanced bacterial inhibition in vitro
and restored antibiotic efficacy in vivo compared to the constituent monotherapies. Neither conessine nor the steroidal
alkaloids induced any detectable toxicity in G. mellonella larvae. The enhanced efficacy of the combination treatments was
most pronounced with conessine and correlated with reduced larval burden of infecting P. aeruginosa. Notably, the
enhanced efficacy of conessine/levofloxacin combinations was only detected in the parent strain and strains that
overexpressed the MexAB-OprM or MexEF-OprN efflux systems.
Conclusions: Steroidal alkaloids from Holarrhena antidysenterica, and particularly the principal active ingredient conessine,
restored levofloxacin efficacy against resistant P. aeruginosa strains possessing efflux-mediated MDR phenotypes. The
compounds should be investigated further as a potential novel therapy.
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Background
Global emergence of multidrug-resistant (MDR) Pseudo-
monas aeruginosa is now a growing threat to antibiotic
therapy. Chromosomally encoded antibiotic efflux mecha-
nisms greatly contribute to antibiotic resistance in this or-
ganism, in particular, the multidrug efflux pumps of the
resistance-nodulation-division (RND) superfamily such as
MexAB-OprM, MexCD-OprJ, MexEF-OprN, and
MexXY-OprM [1, 2]. Clinical isolates of P. aeruginosa are
often identified with mutations in regulatory genes that
result in the over-expression of these RND efflux pumps
and confer a MDR phenotype [1, 3]. The MDR phenotype
occurs due to the broad and overlapping range of anti-
biotic substrates that the RND pumps efflux, particularly
MexAB-OprM [3]. Thus, multidrug efflux pumps
represent potential targets for the development of novel
treatment regimens for MDR P. aeruginosa.
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The use of efflux pump inhibitors (EPIs) as adjuncts
in combination therapies with existing antibiotics is a
potential strategy for preventing efflux-mediated re-
sistance and restoring antibiotic efficacy [4]. Many
synthetic compounds such as phenylalanine-arginine
β-naphthylamide (PAβN), carbonyl cyanide m-chloro-
phenylhydrazone (CCCP), quinoline derivatives, and
1-(1-naphthylmethyl)-piperazine (NMP) display efflux
pump inhibitory activity however none have yet been
developed for clinical application [5, 6]. Some existing
drugs have also been found to possess efflux-pump
inhibitory properties and could be repurposed as re-
sistance modifying agents when administered in com-
bination with antibiotics. Examples include
trimethoprim and the selective serotonin reuptake in-
hibitor sertraline [5, 7, 8].
Currently, a number of naturally-occurring com-
pounds with possible EPI activity including berberine
[9], curcumin [10, 11], and p-coumaric acid [12] are be-
ing actively researched for potential future application
[13, 14]. Extracts made from the stem bark of the plant
Holarrhena antidysenterica (Linn) Wallich belonging to
the family Apocynaceae, are used in Thai and Ayurvedic
traditional medicine to treat amoebic dysentery and
diarrhoea [15, 16]. Steroidal alkaloids present within the
extracts possess antibacterial, anti-diarrhoeal and astrin-
gent properties [15, 16]. Previous studies indicated that
H. antidysenterica extract, and the principal active ingre-
dient alone (the steroidal alkaloid conessine [16]), were
able to restore the inhibitory activity of novobiocin and
rifampicin against extensively drug-resistant Acinetobac-
ter baumannii in vitro [17–19]. Exposure to either H.
antidysenterica extract, or conessine alone, at concentra-
tions that did not result in increased membrane disrup-
tion, resulted in accumulation of the fluorescent dye
Pyronin Y suggesting that both treatments may have
EPI-like properties [19]. Moreover, exposure to cones-
sine restored the MICs of antibiotics against a P. aerugi-
nosa strain over-expressing MexAB-OprM to values
comparable with the wild-type parent and conessine in-
duced the accumulation of Hoechst 33342 in cells
over-expressing the same efflux pump [20].
Previous work has employed Galleria mellonella larvae
to demonstrate enhanced efficacy of putative EPIs in com-
bination with antibiotics versus infections by MDR strains
of P. aeruginosa that over-express various RND efflux
pumps [10, 21]. The aim of this study was to evaluate the
efficacy of combinations of antibiotics with either H. anti-
dysenterica extracts, or the steroidal alkaloid conessine,
using a G. mellonella infection model to determine if these
combinations were toxic, or could treat successfully, infec-
tions with P. aeruginosa strains possessing an efflux-pump
dependent MDR phenotype due to over-expression of ei-
ther MexAB-OprM, MexCD-OprJ or MexEF-OprN.
Methods
Bacteria and growth media
P. aeruginosa strains PAM1020 (PAO1 prototroph,
wild-type); PAM1032 (nalB), MexAB-OprM overex-
pressed; PAM1033 (nfxB), MexCD-OprJ overexpressed;
PAM1034 (nfxC), MexEF-OprN overexpressed; and
PAM1626 (Δmex), MexAB-OprM, MexCD-OprJ and
MexEF-OprN deletion, were a generous gift from Dr. Olga
Lomovskaya, Rempex Pharmaceuticals, USA [22]. The
strains were grown to mid-log phase in Mueller–Hinton
broth (MHB; Merck, Darmstadt, Germany) at 37 °C with
shaking (at 200 rpm) to prepare inocula for antibiotic sus-
ceptibility testing in vitro and efficacy testing in vivo.
Chemicals and G. mellonella larvae
Conessine and the antibiotics ceftazidime, piperacillin,
meropenem, amikacin, and levofloxacin were purchased
from Sigma–Aldrich Ltd. (Dorset, UK). Stock solutions
of antibiotics were prepared in sterile deionized water.
Conessine was made in 70% Tween 80 (Sigma–Aldrich
Ltd., Dorset, UK) and 30% ethanol. Sub-stocks of all an-
tibiotics and conessine used in experiments were dis-
solved in sterile deionized water. G. mellonella larvae
were obtained from UK Waxworms Ltd. (Sheffield, UK).
Stock solutions of steroidal alkaloids from H. antidysen-
terica bark extract were prepared in 100% ethanol as
previously described [15]. Briefly, fresh barks were
washed with distilled water and dried at 60 °C overnight.
Finely powdered bark (4 kg) was macerated with 95%
ethanol (1:2 w/v) to obtain an alcohol extract, evapo-
rated to dryness, and then suspended in methanol. The
suspension was adjusted to pH = 3.2 by addition of HCl
(2 M). The solution was basified to pH = 9 with NaOH
(2 M) and then extracted with chloroform (0.4 L × 5) to
obtain the total alkaloids (25.63 g). Sub-stocks used in
experiments were made in sterile deionized water.
Antibiotic susceptibility testing
MICs of antibiotics (ceftazidime, piperacillin, merope-
nem, amikacin, and levofloxacin), conessine, or steroidal
alkaloids against each of the P. aeruginosa strains were
determined in 96-well microplates as previously de-
scribed [23]. Briefly, doubling dilutions of each anti-
biotic, conessine or steroidal alkaloids were prepared in
MHB and subsequently inoculated with 1.0 × 106 cfu/mL
of P. aeruginosa. The effect of conessine or steroidal al-
kaloids in combination with each antibiotic was mea-
sured by first preparing 96-well plates with doubling
dilutions of each antibiotic in MHB as described above.
Following this, single concentrations of either steroidal
extracts (1024 mg/L) or conessine (MIC0.5–32 mg/L or
MIC0.25–16 mg/L) were added to each well prior to in-
oculation with P. aeruginosa as before. Microplates were
incubated at 37 °C and the MIC was defined as the
Siriyong et al. BMC Complementary and Alternative Medicine          (2018) 18:285 Page 2 of 10
concentration(s) present in the first optically clear well
after 24 h. Each experiment was performed at least
twice. Fractional inhibitory concentration index (FICI)
= (MICdrug + steroidal alkaloids or conessine/MICsteroidal alkaloids
or conessine) + (MICdrug + steroidal alkaloids or conessine/MICanti-
biotic) were calculated for each combination and synergy
was defined as FICI ≤0.5 [24].
Determination of P. aeruginosa viability
P. aeruginosa viability was assessed after 24 h exposure to
levofloxacin (0.125, 1, 2 mg/L), conessine (32 mg/L), or
steroidal alkaloids (1024 mg/L), and combinations of levo-
floxacin with conessine or steroidal alkaloids. Aliquots of
tested compounds were added to 96-well microplate wells
containing MHB, while identical volumes of sterile water
were added to control wells. Microplates were inoculated
with 1.0 × 106 cfu/mL of P. aeruginosa and the plates were
incubated at 37 °C for 24 h. Subsequently, viable bacteria
were determined by serial dilution in MHB and plating on
nutrient agar (NA; Merck, Darmstadt, Germany). Plates
were incubated at 37 °C for 24 h prior to counting col-
onies. Each treatment was replicated in quadruplicate and
a mean value was calculated. Synergy was defined as a ≥
2-log10 decrease in colony count at 24 h by the combin-
ation therapies compared with the most effective single
treatments, as well as a ≥ 2-log10 decrease in colony count
compared with the starting inoculum [25].
G. mellonella model of P. aeruginosa infection
G. mellonella at their final instar larval stage were kept
at room temperature in darkness. Larvae weighing
within the range of 250 to 350 mg were selected for each
experiment to ensure consistency in subsequent drug
administrations and were used within 1 week of receipt.
Efficacy of conessine or steroidal alkaloids in combin-
ation with levofloxacin versus G. mellonella larvae in-
fected with the P. aeruginosa strains was carried out
exactly as described previously [21, 23, 26]. Briefly, groups
of 15 larvae were infected with an inoculum of 2.5 ×
103 cfu/mL of P. aeruginosa cells. Treatments with three
doses of conessine or steroidal alkaloids, levofloxacin, and
combinations of these compounds were administered 2, 4,
and 6 h post-infection. Levofloxacin doses of 1 and
0.05 mg/kg were used for P. aeruginosa PAM1020 and
PAM1626 respectively and a dose of 5 mg/kg of levofloxa-
cin was utilized for PAM1032, PAM1033 and PAM1034
[21]. Conessine was administered at 50 mg/kg and ster-
oidal alkaloids at 50, 100 and 200 mg/kg in all tested
strains. The experiments were repeated in triplicate using
larvae from different batches and the data from these rep-
licate experiments were pooled to give n = 45. Survival
data were plotted using the Kaplan–Meier method [27]
and comparisons made between groups using the log-rank
test [28]. In all comparisons with the negative control it
was the uninfected control (rather than the unmanipu-
lated control) that was used. Holm’s correction was ap-
plied to account for multiple comparisons in all tests and
P ≤ 0.05 was considered significant [29].
G. mellonella haemolymph burden
Larval burden of five randomly selected caterpillars from
each treatment group was measured at 24 h intervals
exactly as described previously [10, 21, 26]. Groups of 30
larvae were infected with 2.5 × 103 cfu/mL of P. aerugi-
nosa. Conessine (50 mg/kg) or steroidal alkaloids (50,
100 or 200 mg/kg), levofloxacin (1 or 5 mg/kg), and the
combinations were administered at 2, 4, and 6 h
post-infection. Larvae were incubated in Petri dishes at
37 °C. The detection limit for this assay was 100 cfu/mL
of larval homogenate.
Results
H. antidysenterica steroidal alkaloids and conessine increase
the susceptibility of P. aeruginosa to antibiotics in vitro
Alone, the steroidal alkaloids had no inhibitory action
and the MIC for the parent strain and the strains over-
expressing each of the efflux systems was > 1024 mg/L.
However, deletion of all three efflux systems (PAM1626)
did induce some sensitivity as the MIC for this strain
was 256 mg/L. In contrast, the MIC for conessine was
identical for all of the strains tested: 64 mg/L, suggesting
that conessine is not a substrate for the MexAB-OprM,
MexCD-OprJ, and MexEF-OprN efflux pumps.
The susceptibility of the P. aeruginosa strains to a group
of anti-pseudomonal antibiotics alone or in the presence of
steroidal alkaloids (128 or 1024 mg/L) or conessine (32 mg/
L) is shown in Table 1. In this study, steroidal alkaloids ex-
tract at 1024 mg/L contained approximately 37 mg/L
conessine content [19]. The strain overexpressing the
MexAB-OprM efflux pump (PAM1032) was more resistant
to ceftazidime, piperacillin, meropenem and levofloxacin in
comparison to the parent strain (PAM1020). In contrast,
the strains overexpressing the MexCD-OprJ (PAM1033)
and MexEF-OprN (PAM1034) efflux systems displayed
resistance to levofloxacin only. Deletion of all three efflux
systems (PAM1626) resulted in increased susceptibility to
all of the antibiotics compared to the parent strain. These
results are in accordance with published reports on the
substrate specificity of these efflux pumps [1, 21].
Generally, but with some exceptions, combination of
the steroidal alkaloids or conessine with the antibiotics re-
sulted in minor reductions of the MICs of the antibiotics
versus each of the P. aeruginosa strains tested (Table 1).
However, this enhancement of antibiotic inhibition was
not synergistic as none of the calculated FICI values for
each of the drug combinations was ≤0.5 (Table 1).
Further study of the inhibitory action of the steroidal
alkaloids or conessine in combination with levofloxacin
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was carried out because the fluoroquinolones are known
substrates for all three of the overexpressed efflux sys-
tems studied in this work [1]. Furthermore, in a recent
study that employed the same strains, levofloxacin in
combination with unrelated, putative EPIs generated op-
timal results [21].
The effect of exposure to levofloxacin alone at MIC0.5,
or combinations of levofloxacin with steroidal alkaloids or
conessine, on the viability of the P. aeruginosa strains was
measured using an in vitro 24 h time-kill assay (Table 2).
The P. aeruginosa strain overexpressing the MexCD-OprJ
efflux system (PAM1033) and the triple deletion strain
(PAM1626) were omitted because the levofloxacin MIC of
PAM1033 was unchanged by exposure to either the
alkaloids or conessine, and PAM1626 is already hypersen-
sitive to levofloxacin (Table 1).
Combination of levofloxacin with either the steroidal
alkaloids or conessine did enhance killing of the P.
aeruginosa strains overexpressing MexAB-OprM and
MexEF-OprN compared to the single drug treatments. The
greatest enhancement of killing occurred with combinations
of levofloxacin and conessine. However, similar to the
findings shown in Table 1, the enhanced killing due to the
combination treatments was not sufficiently potent to be
termed synergistic.
In summary, combination of H. antidysenterica
steroidal alkaloids and conessine with antibiotics resulted
in enhanced inhibition in vitro of P. aeruginosa strains
Table 1 MICs of five antibiotics alone and in the presence of Holarrhena antidysenterica steroidal alkaloids or conessine against P.
aeruginosa PAM1020, 1032, 1033, 1034 and 1626
Strain Drug Drug MIC (mg/L) with FIC indexb
Alone Steroidal alkaloidsa Conessinea Drug + Steroidal alkaloids Drug + Conessine
PAM1020 CAZ 1 0.5 1 1.50 1.50
PIP 2 1 2 1.50 1.50
MEM 0.5 0.5 0.25 2.00 1.00
LVX 0.5 0.5 0.25 2.00 1.00
AMK 1 0.5 0.5 1.50 1.00
PAM1032 CAZ 4 2 2 1.50 1.00
PIP 16 16 8 2.00 1.00
MEM 4 4 2 2.00 1.00
LVX 2 1 1 1.50 1.00
AMK 1 0.5 0.5 1.50 1.00
PAM1033 CAZ 1 0.5 1 1.50 1.50
PIP 2 1 2 1.50 1.50
MEM 0.5 0.25 0.5 1.50 1.50
LVX 4 4 4 2.00 1.50
AMK 0.5 0.25 0.5 1.50 1.50
PAM1034 CAZ 1 1 0.5 2.00 1.00
PIP 1 0.5 0.03125 1.50 0.53
MEM 0.5 0.5 0.125 2.00 0.75
LVX 4 2 0.25 1.50 0.56
AMK 0.5 0.25 0.5 1.50 1.50
PAM1626 CAZ 0.5 0.5 0.25 1.50 1.00
PIP 0.5 0.25 0.5 1.00 1.50
MEM 0.0625 0.0625 0.0625 1.50 1.50
LVX 0.03125 0.00781 0.00391 0.75 0.63
AMK 0.5 0.25 0.25 1.00 1.00
CAZ ceftazidime, PIP piperacillin, MEM meropenem, LVX levofloxacin, AMK amikacin
aThe concentration of steroidal alkaloids or conessine added to each well reflected the previously characterized MICs and were selected to be lower than the MIC for
each strain: PAM1020, 1032, 1033, and 1034: Steroidal alkaloids (1024 mg/L), Conessine (32 mg/L); PAM1626: Steroidal alkaloids (128 mg/L), Conessine (32 mg/L)
bFractional inhibitory concentration index (FIC index) where synergistic (≤ 0.5), non- synergistic (> 0.5 - ≤ 4.0), and antagonistic (> 4.0). For the strains where the
steroidal alkaloids did not have a measurable MIC, the highest value tested (1024 mg/L) was used in the FICI calculation to provide a conservative estimate of the
FICI value
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that over-express different efflux-pump systems that can
confer a MDR phenotype.
Combination treatments of levofloxacin with H.
antidysenterica steroidal alkaloids, or conessine, show
enhanced efficacy compared to the component
monotherapies versus G. mellonella larvae infected with
MDR strains of P. aeruginosa
The efficacy of antibiotic combinations with steroidal alka-
loids or conessine were investigated in vivo using the G.
mellonella infection model. Initially, larvae were injected
with triple doses (at 2, 4 and 6 h intervals after the start of
the experiment) of the steroidal alkaloids (up to 200 mg/kg)
or conessine (up to 50 mg/kg) alone to determine if either
were toxic and neither had any detrimental effect on the
larvae after 96 h incubation at 37 °C (Additional file 1).
Preliminary studies showed that combinations of the
steroidal alkaloids or conessine with the antibiotic levo-
floxacin gave the best results so these were investigated
further in detail. Appropriate strain specific dosing regi-
mens of levofloxacin, steroidal alkaloids and conessine
were determined that provided little, or no, therapeutic
benefit to larvae infected with the P. aeruginosa strains
when administered as monotherapies (Additional file 2).
Thus, any enhanced efficacy induced upon administra-
tion of combinations of the antibiotics with the steroidal
alkaloids or conessine could be readily observed.
The effect of triple doses (2, 4 and 6 h post-infection
(p.i)) of levofloxacin in combination with steroidal alkaloids
on the survival and bacterial burden of G. mellonella larvae
infected with P. aeruginosa PAM1032 and PAM1034 is
shown in Fig. 1. Treatment with triple doses of steroidal al-
kaloids alone (50, 100 or 200 mg/kg) had no therapeutic
benefit on all of the strains tested (Fig. 1a and b). Death of
the infected larvae correlated with the recovery of high
numbers of P. aeruginosa PAM1032 or PAM1034 from
within the larvae after just 24 h (Fig. 1c and d respectively).
Similarly, a triple dose of levofloxacin (5 mg/kg) resulted in
only a minor increase in survival of infected larvae com-
pared to infected larvae treated with PBS (Fig. 1a and b)
and the rapid growth of both P. aeruginosa strains within
the larvae was not significantly reduced (Fig. 1c and d).
Notably, treatment with the same triple doses of the
steroidal alkaloids in combination with 5 mg/kg of levo-
floxacin resulted in significantly enhanced survival com-
pared to triple doses of the monotherapies (P < 0.05).
Enhanced survival after combination therapy was most
pronounced with PAM1032 infections but was also
evident with PAM1034 to a lesser extent (Fig. 1a and b).
Furthermore, combination therapy completely prevented
the rapid proliferation of bacteria within the larvae
reflected by large reductions in bacterial burden com-
pared to that seen with the monotherapies over the dur-
ation of the experiment (Fig. 1c and d). The enhanced
efficacy of levofloxacin occurred in a dose-dependent
fashion increasing as the co-administered dose of the
steroidal alkaloids increased. Significantly enhanced efficacy
was only observed with the strains overexpressing
Table 2 Effect of conessine and steroidal alkaloids in combination with levofloxacin on the viability of P. aeruginosa PAM1020,
PAM1032 and PAM1034
Strain Agent (s) Concentration
(mg/L)
Log CFU/ml
Inoculum Untreated control Treatment (±SD) Log reduction
Single treatment at MIC0.5
a PAM1020 Conessine 32 9.47 ± 0.03 0.27
Alkaloids 1024 5.16 ± 0.06 9.74 ± 0.06 8.76 ± 0.01 0.98
LVX 0.125 8.91 ± 0.02 0.83
PAM1032 Conessine 32 9.42 ± 0.01 0.45
Alkaloids 1024 5.44 ± 0.08 9.87 ± 0.14 8.82 ± 0.06 1.05
LVX 1 8.19 ± 0.68 1.68
PAM1034 Conessine 32 9.54 ± 0.09 0.13
Alkaloids 1024 5.64 ± 0.21 9.67 ± 0.02 8.88 ± 0.23 0.79
LVX 2 8.18 ± 0.10 1.49
Combinations at MIC0.5 PAM1020 Conessine + LVX 32 + 0.125 5.16 ± 0.06 9.74 ± 0.06 9.25 ± 0.03 0.49
Alkaloids + LVX 1024 + 0.125 8.12 ± 0.16 1.62
PAM1032 Conessine + LVX 32 + 1 5.44 ± 0.08 9.87 ± 0.14 5.35 ± 0.43 4.52
Alkaloids + LVX 1024 + 1 7.70 ± 0.13 2.17
PAM1034 Conessine + LVX 32 + 2 5.64 ± 0.21 9.67 ± 0.02 5.54 ± 0.09 4.13
Alkaloids + LVX 1024 + 2 6.85 ± 0.67 2.82
aA MIC was not detectable for the steroidal alkaloids so the highest concentration tested was used in this assay
Viability was determined in 96-well microplates after 24 h exposure to the antibiotics in MHB at 37 °C. Data shown is the mean and standard deviation from
quadruple experiments. Highlighted treatments are those that resulted in ≥2 log10 reduction compared to untreated controls
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MexAB-OprM (PAM1032) and MexEF-OprN (PAM1034).
A small enhancement (P < 0.05) in survival was observed in
the parent strain (PAM1020) but only at the highest dose
of steroidal alkaloids administered (Additional file 3a).
No enhancement in survival after combination therapy
was observed in the strain overexpressing MexCD-OprJ
(PAM1033) or the strain with the three efflux-pump
systems deleted (PAM1626) (Additional file 3b and c
respectively).
Similar studies were carried out with combinations of
conessine with levofloxacin rather than the steroidal
alkaloids (Fig. 2). Treatment with a triple dose of cones-
sine (50 mg/kg) alone had no therapeutic effect on larvae
infected with all of the P. aeruginosa strains tested and did
not prevent the rapid increase in bacterial burden of the
inoculated P. aeruginosa strains that occurred after the
first 24 h p.i (Fig. 2). Similarly, strain-specific, triple doses
of levofloxacin alone were administered that resulted in
only a small increase in survival of infected larvae com-
pared to those treated with PBS: PAM1020–1 mg/kg
(Fig. 2a) and PAM1032 or PAM1034 5 mg/kg (Fig. 2b and
c, respectively). Correlating with larval survival, these
Fig. 1 Effect of treatment with combinations of steroidal alkaloids and levofloxacin on survival of G. mellonella larvae infected with P. aeruginosa
PAM1032 (a) and PAM1034 (b), or larval burden of the same strains PAM1032 (c) and PAM1034 (d). All larvae were inoculated with 2.5 × 103 cfu/mL P.
aeruginosa and treated with each agent individually or in combination with three doses at 2, 4 and 6 h post-infection (indicated by the arrows).
Treatments consisted of PBS, steroidal alkaloids (50, 100 or 200 mg/kg), levofloxacin (5 mg/kg), and a combination of steroidal alkaloids with
levofloxacin. Larvae were incubated at 37 °C for 96 h and survival recorded every 24 h. The burden of P. aeruginosa was determined from five
individual larvae every 24 h. For clarity, data for treatment with PBS alone is not shown because the data obtained was similar to that obtained for
steroidal alkaloid treatment alone. * a) and b); combination treatment group with significantly enhanced survival compared with any of the
constituent monotherapies (P < 0.05, log-rank test with Holm’s correction for multiple comparisons). n = 45 (pooled from triplicate experiments). Error
bars indicate ±SEM. LVX, levofloxacin; ALKS, steroidal alkaloids. * c) and d); significant difference in larval burden between groups treated with the
combination of steroidal alkaloids and levofloxacin compared with the constituent monotherapies; n = 5 (P < 0.05, the Mann–Whitney U-test
compared the combination therapy with each monotherapy individually). The black bar represents the median value of larval burden per group
Siriyong et al. BMC Complementary and Alternative Medicine          (2018) 18:285 Page 6 of 10
Fig. 2 Effect of treatment with combinations of conessine and levofloxacin on survival of G. mellonella larvae infected with P. aeruginosa
PAM1020 (a), PAM1032 (b) and PAM1034 (c), or larval burden of the same strains PAM1020 (d), PAM1032 (e) and PAM1034 (f). All larvae were
inoculated with 2.5 × 103 cfu/mL P. aeruginosa and treated with each agent individually or in combination with three doses at 2, 4 and 6 h post-
infection (indicated by the arrows). Treatments consisted of PBS, conessine (50 mg/kg), levofloxacin (1 or 5 mg/kg, indicated on graph), and a
combination of conessine with levofloxacin. Larvae were incubated at 37 °C for 96 h and survival recorded every 24 h. The burden of P.
aeruginosa was determined from five individual larvae every 24 h. For clarity, data for treatment with PBS alone is not shown because the data
obtained was similar to that obtained for conessine treatment alone. *a), b) and c); combination treatment group with significantly enhanced
survival compared with any of the constituent monotherapies (P < 0.05, log-rank test with Holm’s correction for multiple comparisons). n = 45
(pooled from triplicate experiments). Error bars indicate ±SEM. LVX, levofloxacin; CON, conessine. * d), e) and f); significant difference in larval
burden between groups treated with the combination of conessine and levofloxacin compared with the constituent monotherapies; n = 5 (P <
0.05, the Mann–Whitney U-test compared the combination therapy with each monotherapy individually). The black bar represents the median
value of larval burden per group
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doses of levofloxacin resulted in only a minor reduction in
the bacterial burden within the larvae over the 96 h dur-
ation of the experiment (Fig. 2d, e and f).
Treatment with a triple dose of a combination of cones-
sine (50 mg/kg) with the same, strain-specific levofloxacin
doses mentioned previously, resulted in significantly en-
hanced survival compared to triple doses of the monother-
apies (P < 0.05). Enhanced efficacy was most notable versus
the P. aeruginosa strain overexpressing the MexAB-OprM
efflux pump (PAM1032) (Fig. 2b) but the combination
therapy also resulted in enhanced survival of the parent
strain (PAM1020) (Fig. 2a) and the strain overexpressing
MexEF-OprN (PAM1034) (Fig. 2c). As before, the combin-
ation treatment resulted in correlative reductions in bacter-
ial burden within infected larvae over the 96 h duration of
the experiment with the inhibitory effect on bacterial
growth being most notable for PAM1032 (Fig. 2e) but was
also evident in larvae infected with either PAM1020
(Fig. 2d) or PAM1034 (Fig. 2f). As shown with the steroidal
alkaloids previously, combination therapy of conessine with
levofloxacin did not result in enhanced survival of larvae in-
fected with either PAM1033 (overexpressing MexCD-OprJ)
or PAM1626 (the strain with the three efflux-pump systems
deleted) (Additional file 4a and b respectively).
In summary, combination therapies of conessine or ster-
oidal alkaloids with levofloxacin restored antibiotic efficacy in
vivo versus infections with strains of P. aeruginosa overex-
pressing either the MexAB-OprM or MexEF-OprN efflux
pumps. These observations were supported by the results ob-
tained in vitro. The enhanced efficacy of the combination
treatments was reflected in high levels of larval survival that
correlated with reduced larval burden of the infecting patho-
gens. In some cases the combination treatment completely
eradicated detectable bacteria within the larvae with numbers
remaining below the level of detection (≤ 2 log10 cfu/mL).
Discussion
Mutations that result in the over-expression of efflux pumps
and confer a MDR phenotype on P. aeruginosa strains are
frequently isolated from infected patients [1, 3]. Thus, the
overexpression of efflux pumps such as MexAB-OprM,
MexCD-OprJ, MexEF-OprN, and MexXY-OprM render
many therapeutic options for serious P. aeruginosa infections
redundant. As a consequence, many studies have addressed
the possibility of co-administering EPIs with antibiotics to re-
store the clinical efficacy of antibiotics that are otherwise
rendered ineffective [4, 5].
A previous study conducted in the corresponding author’s
lab employed well-characterized P. aeruginosa strains (gifted
by [22]) that over-express the RND efflux pumps in conjunc-
tion with a G. mellonella larva infection model [21]. Notably,
this demonstrated that infection with strains that overexpress
efflux pumps resulted in antibiotic treatment failure in G.
mellonella larvae, reproducing the treatment outcomes seen
in human patients, and illustrating that this invertebrate
model can be employed to identify novel treatments for
MDR P. aeruginosa infections. Subsequently, the model was
used to identify putative EPI/antibiotic combinations that re-
stored antibiotic efficacy versus efflux-pump mediated P. aer-
uginosa infections in vivo [10, 21]. The present work has
used the same P. aeruginosa strains and presents evidence
that combinations of levofloxacin with H. antidysenterica ex-
tract, and the principal active ingredient alone (the steroidal
alkaloid conessine), show no toxicity in vivo but enhanced ef-
ficacy in vitro and in vivo and represent a novel treatment
option meriting further investigation.
Available evidence suggests that H. antidysenterica ster-
oidal crude extract, and conessine may be acting as EPIs [19,
20]. The steroidal extract and the alkaloid conessine have re-
cently been reported to enhance antibiotic activity due to
interference with the AdeIJK efflux pump in A. baumannii
[19] which is functionally equivalent to the MexAB-OprM
pump of P. aeruginosa [30]. Furthermore, conessine restored
antibiotic susceptibility to an otherwise resistant P. aerugi-
nosa strain that overexpressed the MexAB-OprM efflux
pump [20]. The data reported in the present study does not
demonstrate that either the steroidal extracts or conessine
are EPIs but is consistent with this hypothesis. For example,
both the steroidal extracts and conessine restored the in vivo
efficacy of levofloxacin only against the parent strain (where
MexAB-OprM is known to be constitutively expressed; [3])
and the strains overexpressing the MexAB-OprM or
MexEF-OprN efflux pumps. They had no restorative effect
on the strain overexpressing MexCD-OprJ or the strain with
all three of the Mex efflux pumps deleted. This specificity for
certain Mex efflux systems does imply that compounds
within the extract and conessine could be acting as EPIs.
Furthermore, the finding that the restorative effect on levo-
floxacin efficacy was much less potent with the crude extract
of steroidal alkaloids compared to the principal active ingre-
dient alone (the steroidal alkaloid conessine; [16]) also sug-
gests that it is conessine that posesses these EPI-like
properties. Nonetheless, it also cannot be discounted that the
restorative effect of the extract and conessine on levofloxacin
efficacy with the strains containing the nalB (MexAB-OprM
overexpressed) or nfxC (MexEF-OprN overexpressed) muta-
tions could be explained by other unknown effects of these
mutations that are unconnected with the over-expression of
the two Mex efflux pumps.
Irrespective of the precise mode of action, the ability of
conessine to restore antibiotic efficacy versus MDR P. aeru-
ginosa infections merits further investigation and develop-
ment for potential clinical application. Precise evaluation of
the toxicity of H. antidysenterica bark extracts has not been
carried out in humans. A study of acute and subacute tox-
icity of the methanol extract of a related plant, Holarrhena
floribunda, that also contains conessine and is widely used
to treat gastrointestinal disorders in Cameroon, revealed a
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LD50 of 7 g/kg for female rats, indicating low levels of tox-
icity [31]. However, conessine alone was found to have an
LD50 of 28.7 mg/kg after administration to mice intraperi-
toneally and was also observed to depress the heart and
central nervous system [32]. Notably, the dose employed in
the present study that elicited the optimal restorative effect
on levofloxacin efficacy was higher at 50 mg/kg. Clearly,
additional studies are required to identify if either the plant
extracts or conessine alone are able to be safely used in hu-
man patients. Furthermore, showing that the steroidal ex-
tracts and conessine restore antibiotic efficacy in G.
mellonella larvae does not mean that the same effects
would be observed in mammals. Whilst this study has once
again revealed the success of the G. mellonella infection
model as a ‘first in vivo’ test for novel antimicrobial therap-
ies, additional studies will also need to determine if the
therapeutic benefit observed here also occurs in more trad-
itional mammalian infection models.
Conclusions
In summary, combination therapies of conessine or ster-
oidal alkaloids with levofloxacin restored the efficacy of
the antibiotic in vivo versus infections of G. mellonella lar-
vae with strains overexpressing either the MexAB-OprM
or MexEF-OprN efflux pumps. No restorative effect was
observed on infections with strains overexpressing
MexCD-OprJ or the strain with all three of the Mex efflux
pumps deleted. The enhanced efficacy of the combination
treatments was reflected in high levels of larval survival
that correlated with large reductions in larval burden of
the infecting pathogens.
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Additional file 1: Raw data for steroidal alkaloid and conessine toxicity
in vivo. (XLS 39 kb)
Additional file 2: Raw data for single treatments in vivo. (XLS 198 kb)
Additional file 3: Effect of treatment with combinations of steroidal
alkaloids and levofloxacin on survival of Galleria mellonella larvae infected
with Pseudomonas aeruginosa PAM1020 (a), PAM1033 (b) and PAM1626 (c).
All larvae were inoculated with 2.5 × 103 cfu/mL P. aeruginosa and treated
with each agent individually or in combination with three doses at 2, 4 and
6 h post-infection (indicated by the arrows). Treatments consisted of PBS,
steroidal alkaloids (50, 100 or 200 mg/kg), levofloxacin (0.05, 1 or 5 mg/kg),
and a combination of steroidal alkaloids with levofloxacin. Larvae were incu-
bated at 37 °C for 96 h and survival recorded every 24 h. * combination
treatment group with significantly enhanced survival compared with any of
the constituent monotherapies (P < 0.05, log-rank test with Holm’s correc-
tion for multiple comparisons). n = 30 (pooled from duplicate experiments).
LVX, levofloxacin; ALKS, steroidal alkaloids. (PNG 117 kb)
Additional file 4: Effect of treatment with combinations of conessine and
levofloxacin on survival of Galleria mellonella larvae infected with Pseudomonas
aeruginosa PAM1033 (a) and PAM1626 (b). All larvae were inoculated with
2.5 × 103 cfu/mL P. aeruginosa and treated with each agent individually or in
combination with three doses at 2, 4 and 6 h post-infection (indicated by the
arrows). Treatments consisted of PBS, conessine (50 mg/kg), levofloxacin (0.05
or 5 mg/kg), and a combination of conessine with levofloxacin. Larvae were
incubated at 37oC for 96 h and survival recorded every 24 h. * combination
treatment group with significantly enhanced survival compared with any of
the constituent monotherapies (P< 0.05, log-rank test with Holm’s correction
for multiple comparisons). n= 30 (pooled from duplicate experiments). LVX,
levofloxacin; CON, conessine. (PNG 89 kb)
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